Axillary Hyperhidrosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Axillary Hyperhidrosis – Pipeline Review, H2 2016’, provides an overview of the Axillary Hyperhidrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis

The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects

The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Brickell Biotech, Inc.

Dermira Inc.

GlaxoSmithKline Plc

Revance Therapeutics, Inc.

TheraVida, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Axillary Hyperhidrosis Overview 6

Therapeutics Development 7

Pipeline Products for Axillary Hyperhidrosis - Overview 7

Axillary Hyperhidrosis - Therapeutics under Development by Companies 8

Axillary Hyperhidrosis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Axillary Hyperhidrosis - Products under Development by Companies 11

Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12

Allergan Plc 12

Brickell Biotech, Inc. 13

Dermira Inc. 14

GlaxoSmithKline Plc 15

Revance Therapeutics, Inc. 16

TheraVida, Inc. 17

Axillary Hyperhidrosis - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

(oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ANT-1403 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

botulinum toxinA - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

daxibotulinumtoxinA - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

glycopyrronium tosylate - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

sofpironium bromide - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

umeclidinium bromide - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Axillary Hyperhidrosis - Dormant Projects 41

Axillary Hyperhidrosis - Product Development Milestones 42

Featured News & Press Releases 42

Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis 42

Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating 45

Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis 46

Jan 07, 2016: Dermira Provides DRM04 Development Program Update 47

Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 47

Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis 49

Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines 49

Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 50

Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis 51

Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 52

Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis 52

Jan 12, 2015: Revance Therapeutics Provides Clinical Program Milestone Update For RT001 54

Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis 54

Mar 19, 2014: Anterios Announces Development Of Next Generation Injectable Botulinum Product 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Number of Products under Development for Axillary Hyperhidrosis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Axillary Hyperhidrosis – Pipeline by Allergan Plc, H2 2016 12

Axillary Hyperhidrosis – Pipeline by Brickell Biotech, Inc., H2 2016 13

Axillary Hyperhidrosis – Pipeline by Dermira Inc., H2 2016 14

Axillary Hyperhidrosis – Pipeline by GlaxoSmithKline Plc, H2 2016 15

Axillary Hyperhidrosis – Pipeline by Revance Therapeutics, Inc., H2 2016 16

Axillary Hyperhidrosis – Pipeline by TheraVida, Inc., H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Axillary Hyperhidrosis – Dormant Projects, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for Axillary Hyperhidrosis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports